Onkologisches Zentrum
EMBER-4
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
Die Studie eignet sich für: ER+, HER2- invasiver Brustkrebs im Frühstadium